| Glutathione |
Trichloro(terpyridine)ruthenium(iii)/multi-wall carbon nanotubes (TChPRu-MWCNT) |
0.6–56.8 μM |
0.3 μM |
122
|
| Gallic acid |
SiO2 nanoparticles |
8.0 × 10−7 to 1.0 × 10−4 M |
2.5 × 10−7 M |
127
|
| Gallic acid |
Zirconia nanoparticles/choline chloride/gold nanoparticles (ZrO2NPs–ChCl–AuNPs) |
0.22–55 μM |
25 nM |
128
|
| Gallic acid |
TiO2 NPs |
2.5 × 10−6 to 1.5 × 10−4 M |
9.4 × 10−7 M |
129
|
| Citric acid |
MIL-101(Fe) |
5.0 to 100 μM |
4.0 μM |
130
|
| Dopamine |
N,N′(2,3-Dihydroxybenzylidene)-1,4-phenylenediamine (DHBPD) and TiO2 nanoparticles |
0.08–20.0 μM |
3.14 × 10−8 M |
138
|
| Dopamine |
Graphene oxide (GO)/lanthanum (La) complex |
0.01–400.0 μM |
0.32 nM |
139
|
| Epinephrine |
Carbon nanotube (CNT)/molybdenum(vi) complex (MC) |
0.09 to 750.0 μM |
49 nM |
141
|
| Epinephrine |
Hydrophilic ionic liquid 1-methyl-3-butylimidazolium bromide [MBIDZ]Br/carbon nanotube (CNT) |
0.3–450 μM |
0.09 μM |
142
|
| Epinephrine |
Graphene oxide (GO)/2-(5-ethyl-2,4-dihydroxyphenyl)-5,7-dimethyl-4H-pyrido[2,3-d][1,3]thiazine-4-one (EDDPT) |
1.5–600.0 μM |
0.65 μM |
143
|
| Epinephrine |
2,2′-[1,2-Butanediylbis(nitriloethylidyne)]-bishydroquinone (BBNBH)/TiO2 nanoparticles |
1.0–600.0 μM |
0.2 μM |
144
|
| Epinephrine |
ZrO2 nanoparticles |
2.0 × 10−7 to 2.2 × 10−3 M |
9.5 × 10−8 M |
145
|
| Norepinephrine |
ZrO2 nanoparticles |
1.0 × 10−7 to 2.0 × 10−3 M |
8.95 × 10−8 M |
147
|
| Norepinephrine |
Ferrocene dicarboxylic acid (FCD)/carbon nanotube(CNT) |
0.03–500.0 μM |
22.0 nM |
148
|
| Norepinephrine |
2,2′-[1,2-Ethanediylbis (nitriloethylidyne)]-bis-hydroquinone (EBNBH)/carbon nanotube(CNT) |
0.1–1100.0 μM |
8.2 × 10−8 M |
149
|
| Levodopa |
Polyglycine/zinc oxide nanoparticles/multi-walled carbon nanotubes PG/ZnO/MWCNTs |
5.0–500.0 μM |
0.08 μM |
150
|
| Levodopa |
2,7-Bis(ferrocenylethyl)fluoren-9-one (2,7-BF)/carbon nanotube (CNT) |
0.1–700.0 μM |
58 nM |
151
|
|
l-Cysteine |
MgO nanoparticle/acetylferrocene (AF) |
0.1–700.0 μM |
30.0 nM |
159
|
| Arginine |
CdSe quantum dot (QD)/multi-walled carbon nanotube (MWCNT) |
0.287 to 33 670 μM |
0.081 μM |
160
|
| Alanine |
0.158 μM |
| Methionine |
0.094 μM |
| Cysteine |
0.116 μM |
| Tryptophan |
Mesoporous silica nanoparticles (MSNs) |
0.05–600 μM |
1.13 × 10−8 M |
163
|
| Tyrosine |
0.3–600.0 μM |
4.97 × 10−8 M |
| Tryptophan |
ZnFe2O4 nanoparticles |
0.1–200.0 μM |
0.04 μM |
164
|
| Tyrosine |
0.4–175.0 μM |
0.10 μM |
| Melatonin |
SnO2–Co3O4@rGO nanocomposite/ionic liuid (SnO2–Co3O4@rGO/IL) |
0.02–6.00 μM |
4.1 nM |
165
|
| Tryptophan |
4.1–3.2 nM |
3.2 nM |
| Isoproterenol |
Multiwall carbon nanotube (MWCNT)/ionic liquid (1-butyl-3-methylimidazolium hexafluoro phosphate ([C4mim]-[PF6])) (IL) |
1.0–520 μM |
0.85 μM |
167
|
| Isoproterenol |
1-(4-Bromobenzyl)-4-ferrocenyl-1H-[1,2,3]-triazole (1,4-BBFT)/hydrophilic ionic liquid (n-hexyl-3-methylimidazolium hexafluoro phosphate)/graphene (1,4-BBFT/IL/G) |
6.0 × 10−8 to 7.0 × 10−4 M |
12.0 nM |
169
|
| Isoproterenol |
Ferrocenemonocarboxylic acid (FMA)/carbon nanotube (CNT) |
0.5–50.0 μM |
0.2 μM |
170
|
| Isoproterenol |
2,7-Bis(ferrocenyl ethyl)fluoren-9-one (2,7-BF)/carbon nanotube (CNT) |
0.08–700.5 μM |
26.0 ± 2 nM |
171
|
| Buprenorphine |
Molecularly imprinted polymer (MIP)/nanoparticles multiwalled carbon nanotubes (MWCNTs) |
1 nM to 50 μM |
0.6 nM |
174
|
| Acetaminophen |
Zinc ferrite nanoparticles (ZnFe2O4 NPs) |
6.5–135 μM |
0.4 μM |
175
|
| Epinephrine |
5–100 μM |
0.7 μM |
| Melatonin |
6.5–145 μM |
3.0 μM |
| Melatonin |
Al2O3-supported palladium nanoparticles |
6.0 nM to 1.4 mM |
21.6 nM |
176
|
| Dopamine |
50 nM to 1.45 mM |
36.5 nM |
| Acetaminophen |
40 nM to 1.4 mM |
36.5 nM |
